Fate Therapeutics Inc (FATE) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fate Therapeutics Inc. faces a significant risk if its common stock is delisted from the Nasdaq Global Market, as this would negatively impact the liquidity and market price of its shares. The company must adhere to Nasdaq’s minimum requirements, such as maintaining a closing bid price of at least $1.00 per share, to avoid delisting. Failure to meet these criteria could hinder Fate Therapeutics’ ability to raise funds and materially affect the value of investments in the company. This potential delisting poses a substantial threat to the company’s financial stability and investor confidence.
The average FATE stock price target is $4.41, implying 290.27% upside potential.
To learn more about Fate Therapeutics Inc’s risk factors, click here.